Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > Oral Small-Molecule 3CLpro Inhibitor SYH2055 Against SAR-CoV-2 Obtains Clinical Trial Approval

Oral Small-Molecule 3CLpro Inhibitor SYH2055 Against SAR-CoV-2 Obtains Clinical Trial Approval

December 07, 2022

微信截图_20221208081057.png

Previous: CSPC's Innovative Drug Research Results Selected for the 2022 ASH Annual Meeting

Next: CSPC Selected as Mercer China Healthiest Workplace

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat